GILD

Business Context and Reporting Period

Company: Gilead Sciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2000
Business Overview: Gilead is an independent biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for antiviral, anti-infective, and oncology applications. The company relies heavily on a portfolio of four approved products: AmBisome (antifungal), Tamiflu (influenza, marketed by partner Hoffmann-La Roche), VISTIDE (CMV retinitis), and DaunoXome (Kaposi's sarcoma). The company also maintains a robust pipeline, most notably tenofovir DF for HIV and adefovir dipivoxil for Hepatitis B.

Key Financial Metrics

Note: All share and per-share amounts have been restated to reflect a two-for-one stock split implemented on February 22, 2001.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 16% to $195.6 million in 2000, driven primarily by a 9% increase in AmBisome sales ($141.1 million) and the initiation of royalty recognition from Tamiflu sales ($9.6 million).
• Accounting Change: The company adopted Staff Accounting Bulletin No. 101 (SAB 101) regarding revenue recognition. This resulted in a cumulative effect charge of $13.7 million, increasing the net loss for the year. Without this charge, the loss would have been $43.1 million.
• Debt Financing: In December 2000, Gilead issued $250 million of 5% convertible subordinated notes due 2007, significantly increasing cash reserves and long-term debt obligations.
• Operating Expenses: Research and Development (R&D) expenses rose 19% to $131.6 million due to Phase III trials for tenofovir DF and adefovir dipivoxil, and upfront payments for new oncology licenses. Selling, General, and Administrative (SG&A) expenses decreased 17% to $82.8 million, largely due to the absence of $18.3 million in merger-related expenses recorded in 1999.

Guidance, Outlook, and Risks

• Product Pipeline: Management anticipates filing for U.S. and European approval of tenofovir DF for HIV in mid-2001. Preliminary Phase III data showed significant reduction in HIV viral loads. Adefovir dipivoxil for Hepatitis B is also in Phase III trials.
• Financial Outlook: The company expects to operate at a loss for the foreseeable future. R&D expenses are projected to increase 20-30% in 2001, and SG&A expenses are expected to rise 25-40% to support the commercial launch of tenofovir DF.
• Key Risks:
  • Product Concentration: AmBisome accounted for 72% of total revenues in 2000. A significant reduction in AmBisome sales would materially impact operating income.
  • Regulatory Uncertainty: Approval of pipeline products is not guaranteed. The company previously discontinued adefovir dipivoxil for HIV due to kidney toxicity concerns.
  • Foreign Currency: A significant majority of sales are denominated in foreign currencies. A stronger U.S. dollar negatively impacts reported revenues and gross margins.
  • Collaboration Dependence: Revenue from Tamiflu depends on Hoffmann-La Roche's marketing efforts, and U.S. AmBisome sales depend on co-promotion with Fujisawa.

Investor Verification Checklist

• AmBisome Market Share: Verify the impact of new competitive antifungal products (e.g., caspofungin, voriconazole) on AmBisome sales volumes and pricing power.
• Tenofovir DF Approval Timeline: Confirm the status of the New Drug Application (NDA) filing expected in mid-2001 and the likelihood of FDA approval.
• Foreign Exchange Exposure: Assess the sensitivity of future earnings to fluctuations in the Euro and British Pound against the U.S. Dollar.
• Debt Covenants: Review the terms of the new $250 million convertible notes and the $10 million line of credit for restrictive covenants.
• Accounts Receivable Quality: Examine the aging of receivables in Greece, Spain, and Italy, where $10.9 million was more than 120 days past due as of year-end.